Emerging Trends to Drive Atherosclerosis Drugs Market Growth at 3.5% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Atherosclerosis Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size of atherosclerosis drugs has been expanding progressively over recent years. It is projected to escalate from $49.89 billion in 2024 to $50.91 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 2.0%. The growth witnessed in the historic period is due to factors like cholesterol management, blood pressure control, discontinuation of smoking programs, research and development, and advances in diagnostics.

How Will the Atherosclerosis Drugs Market Size Evolve and Grow by 2029?
The market for atherosclerosis medications is predicted to experience consistent expansion in the upcoming years. It is estimated to reach "$58.36 billion by 2029 with a compound annual growth rate (CAGR) of 3.5%. The projected increase during this period can be linked to the rise in novel treatments, precision medicine, inflammation and immunotherapy, and advances in lipid management, as well as regulatory backing. Key trends anticipated for the forecast period encompass biologic treatments, gene manipulation and therapy, combined therapies, customised treatment strategies, and the use of remote monitoring and telemedicine.

View the full report here:
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

What Drivers Are Propelling the Growth of Atherosclerosis Drugs Market Forward?
The atherosclerosis drug market's growth is projected to be spurred by the rising incidence of cardiovascular ailments. The term "cardiovascular diseases" encompasses all disorders that impact the heart and blood vessels. Atherosclerosis is characterized by an accumulation of fats, cholesterol, and other elements on an individual's arterial walls. Conditions like coronary heart disease and stroke are often the result of atherosclerosis, a circumstance where plaque builds up within the arteries. Atherosclerosis medications are employed to lessen the likelihood of adverse effects from cardiovascular diseases by managing contributing factors such as elevated cholesterol and blood clot formations. For example, in September 2024, the Minnesota Department of Health, a state health agency in the US, reported that around 30% of Minnesota's adult population (roughly 1.4 million people) were diagnosed with high blood pressure in 2023. In 2022, diseases caused by hypertension were listed as the primary or contributing cause of death for 14,225 inhabitants, accounting for nearly 28% of the state's total deaths. Consequently, the atherosclerosis drug market will expand due to the growing prevalence of cardiovascular diseases.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

Which Emerging Trends Are Transforming the Atherosclerosis Drugs Market in 2025?
One observable trend in the atherosclerosis drugs market is the emphasis on product innovation. Major players in this market, in an effort to maintain their standing, are creating unique drugs and getting them approved. As a case in point, in March 2024, Wegovy (semaglutide) was endorsed by Novo Nordisk A/S, a health company based in Denmark, for the reduction of cardiovascular risk in individuals battling obesity or overweight problems. This novel weight loss medication, the first of its kind, is designed to mitigate the risk of serious cardiovascular events in adults with obesity or overweight instances coupled with established cardiovascular disease. This dual-purpose drug not only assists in managing obesity but also ensures significant prevention of severe cardiovascular issues thereby potentially increasing the quality of patient outcomes and life expectancy.

What Are the Key Segments in the Atherosclerosis Drugs Market?
The atherosclerosis drugs market covered in this report is segmented -

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12621&type=smp

Who Are the Key Players Shaping the Atherosclerosis Drugs Market's Competitive Landscape?
Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

What Geographic Markets Are Powering Growth in the Atherosclerosis Drugs Market?
North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12621

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.